EA029757B1 - ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ - Google Patents

ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ Download PDF

Info

Publication number
EA029757B1
EA029757B1 EA201691164A EA201691164A EA029757B1 EA 029757 B1 EA029757 B1 EA 029757B1 EA 201691164 A EA201691164 A EA 201691164A EA 201691164 A EA201691164 A EA 201691164A EA 029757 B1 EA029757 B1 EA 029757B1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyrazolo
pyridin
carboxylic acid
yloxy
dioxo
Prior art date
Application number
EA201691164A
Other languages
English (en)
Russian (ru)
Other versions
EA201691164A1 (ru
Inventor
Роберт Л. Хадкинс
Эллисон Л. Зулли
Original Assignee
Игнита, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Игнита, Инк. filed Critical Игнита, Инк.
Publication of EA201691164A1 publication Critical patent/EA201691164A1/ru
Publication of EA029757B1 publication Critical patent/EA029757B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA201691164A 2013-12-26 2014-12-18 ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ EA029757B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361920819P 2013-12-26 2013-12-26
PCT/US2014/071040 WO2015100117A1 (en) 2013-12-26 2014-12-18 Pyrazolo[1,5-a]pyridine derivatives and methods of their use

Publications (2)

Publication Number Publication Date
EA201691164A1 EA201691164A1 (ru) 2016-12-30
EA029757B1 true EA029757B1 (ru) 2018-05-31

Family

ID=52293273

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201691164A EA029757B1 (ru) 2013-12-26 2014-12-18 ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201890061A EA201890061A3 (ru) 2013-12-26 2014-12-18 Производные пиразоло[1,5-a]пиридина и способы их применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201890061A EA201890061A3 (ru) 2013-12-26 2014-12-18 Производные пиразоло[1,5-a]пиридина и способы их применения

Country Status (22)

Country Link
US (2) US9914731B2 (enExample)
EP (2) EP3087070B1 (enExample)
JP (1) JP2017500362A (enExample)
KR (1) KR20160110390A (enExample)
CN (1) CN106029661B (enExample)
AU (1) AU2014370186A1 (enExample)
BR (1) BR112016015057A2 (enExample)
CA (1) CA2934667A1 (enExample)
CL (1) CL2016001604A1 (enExample)
DK (1) DK3087070T3 (enExample)
EA (2) EA029757B1 (enExample)
ES (1) ES2654931T3 (enExample)
HU (1) HUE037579T2 (enExample)
IL (1) IL246311A0 (enExample)
MX (1) MX2016008445A (enExample)
NO (1) NO3014707T3 (enExample)
PH (1) PH12016501232A1 (enExample)
PL (1) PL3087070T3 (enExample)
PT (1) PT3087070T (enExample)
SG (1) SG11201605207PA (enExample)
SI (1) SI3087070T1 (enExample)
WO (1) WO2015100117A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3322706T3 (da) * 2015-07-16 2021-02-01 Array Biopharma Inc Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer
CN106467541B (zh) * 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
CN106543145B (zh) * 2016-10-28 2019-07-19 山西医科大学 c-Met激酶抑剂3-(4-氟苯基)嘧啶酮-5-甲酸酰胺衍生物、制备方法与应用
CA3047580A1 (en) * 2016-12-23 2018-07-26 Plexxikon Inc. Compounds and methods for cdk8 modulation and indications therefor
CA3049136C (en) 2017-01-18 2022-06-14 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2019101178A1 (zh) * 2017-11-24 2019-05-31 南京明德新药研发股份有限公司 作为c-MET/AXL抑制剂的尿嘧啶类化合物
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CA3087354C (en) 2018-01-18 2023-01-03 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
PL3842425T3 (pl) * 2018-08-24 2024-08-19 Transthera Sciences (Nanjing), Inc. Nowy inhibitor będący pochodną chinoliny
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110467616B (zh) * 2019-07-01 2021-12-21 江西科技师范大学 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用
CN110330479A (zh) * 2019-07-19 2019-10-15 南京华威医药科技集团有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途
KR102826937B1 (ko) 2019-09-06 2025-07-01 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 Axl 및 c-Met 키나아제 억제 활성을 갖는 화합물 및 이의 제조와 응용
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CA3178450A1 (en) 2020-03-30 2021-10-07 Hutchison Medipharma Limited Amide compounds and uses thereof
EP4371978A4 (en) * 2021-07-13 2025-09-10 Nippon Soda Co PROCESS FOR PRODUCING A URACIL COMPOUND
IT202100022682A1 (it) * 2021-09-01 2023-03-01 Luigi Frati Derivati pirimidinici e loro uso nel trattamento di tumori
CN116655626B (zh) * 2023-05-24 2025-03-11 遵义医科大学 一种含咪唑并[l,2-a]吡啶骨架的环丙二酰胺化合物及其制备方法和用途
WO2025034912A2 (en) * 2023-08-07 2025-02-13 Cogent Biosciences, Inc. Compounds for fgfr inhibition
WO2025111224A1 (en) * 2023-11-21 2025-05-30 Fmc Corporation Linked bicyclic compounds for controlling and combating invertebrate pests

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2103620A1 (en) * 2006-12-12 2009-09-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CN102827186A (zh) * 2011-06-16 2012-12-19 中国科学院上海药物研究所 一类吡啶并五元杂环衍生物及其制备方法和用途
WO2013180949A1 (en) * 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
RU2008139599A (ru) * 2006-03-07 2010-04-20 Эррэй Биофарма Инк. (Us) Гетеробициклические производные пиразола и способы их применения
EP1972628A1 (en) 2007-03-21 2008-09-24 Schwarz Pharma Ag Indolizines and aza-analog derivatives thereof as CNS active compounds
JP2011530511A (ja) 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
EP2719699B1 (en) * 2009-12-31 2015-07-08 Hutchison Medipharma Limited Certain triazolopyrazines, compositions thereof and methods of use therefor
JP5959541B2 (ja) * 2011-02-25 2016-08-02 ノバルティス アーゲー Trk阻害剤としてのピラゾロ[1,5−a]ピリジン
AU2012294917A1 (en) * 2011-08-10 2014-03-20 Merck Patent Gmbh Pyrido-pyrimidine derivatives
KR20140064971A (ko) * 2011-09-19 2014-05-28 제넨테크, 인크. c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료
UY34451A (es) * 2011-11-14 2013-05-31 Cephalon Inc Derivados de uracilo como inhibidores de la quinasa axl y c-met

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2103620A1 (en) * 2006-12-12 2009-09-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CN102827186A (zh) * 2011-06-16 2012-12-19 中国科学院上海药物研究所 一类吡啶并五元杂环衍生物及其制备方法和用途
WO2013180949A1 (en) * 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use

Also Published As

Publication number Publication date
EA201890061A2 (ru) 2018-05-31
CA2934667A1 (en) 2015-07-02
PL3087070T3 (pl) 2018-03-30
PT3087070T (pt) 2018-01-30
NO3014707T3 (enExample) 2018-01-06
AU2014370186A2 (en) 2016-07-21
CN106029661B (zh) 2017-11-03
US9914731B2 (en) 2018-03-13
JP2017500362A (ja) 2017-01-05
US20180148447A1 (en) 2018-05-31
PH12016501232A1 (en) 2016-08-15
HUE037579T2 (hu) 2018-09-28
ES2654931T3 (es) 2018-02-15
WO2015100117A1 (en) 2015-07-02
CN106029661A (zh) 2016-10-12
SI3087070T1 (en) 2018-01-31
BR112016015057A2 (pt) 2017-08-08
AU2014370186A1 (en) 2016-07-14
EA201691164A1 (ru) 2016-12-30
MX2016008445A (es) 2016-10-28
KR20160110390A (ko) 2016-09-21
EP3087070B1 (en) 2017-11-08
IL246311A0 (en) 2016-08-02
CL2016001604A1 (es) 2017-05-26
DK3087070T3 (en) 2017-12-04
EA201890061A3 (ru) 2018-09-28
SG11201605207PA (en) 2016-07-28
US20160318929A1 (en) 2016-11-03
EP3087070A1 (en) 2016-11-02
EP3309160A1 (en) 2018-04-18

Similar Documents

Publication Publication Date Title
EA029757B1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP6903790B2 (ja) Fgfr抑制剤としての二環式複素環
AU2016219822B2 (en) Bicyclic heterocycles as FGFR inhibitors
DK2805940T3 (en) PYRAZINE CARBOXAMIDE COMPOUND
US8933103B2 (en) Pyridone derivatives
KR102038462B1 (ko) Pi3k의 활성 또는 기능의 억제제의 용도
IL257481A (en) Modified quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof
KR20190014505A (ko) 이소퀴놀린-3-일 카르복스아마이드 및 이의 제제와 용도
CN107922431A (zh) Hpk1抑制剂及其使用方法
CN113773308A (zh) Rho激酶抑制剂
AU2012288969A1 (en) Substituted quinolines and their use as medicaments
JP2019507766A (ja) 線維症の治療のための新規化合物及びその医薬組成物
CN103012399A (zh) 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用
WO2013100672A1 (ko) 단백질 키나아제 저해활성을 가지는 3,6-이치환된 인다졸 유도체
CN104837844A (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
AU2018320416B2 (en) Pyridylpyridone compounds
TWI869674B (zh) 雜芳基衍生化合物及其用途
KR102731945B1 (ko) 아자인돌릴피리돈 및 디아자인돌릴피리돈 화합물
CN120712252A (zh) 包含sos1抑制剂和抗癌药物的用于治疗癌症的药物组合物
HK40064586A (en) Rho kinase inhibitors
HK40062732A (en) Rho kinase inhibitors
HK40062730A (en) Rho kinase inhibitors
HK40040495A (en) Pyrazole derivatives as malt1 inhibitors
EA050669B1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU